tiprankstipranks
Ionis Pharmaceuticals Inc. (IONS)
NASDAQ:IONS
US Market
IONS
Ionis Pharmaceuticals
RESEARCH TOOLSreports
Want to see IONS full AI Analyst Report?

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

1,544 Followers
See the Price Targets and Ratings of:

IONS Analyst Ratings

Strong Buy
19Ratings
Strong Buy
17 Buy
2 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Ionis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$104.61
▲(38.17% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $104.61 with a high forecast of $130.00 and a low forecast of $75.00. The average price target represents a 38.17% change from the last price of $75.71.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","82":"$82","131":"$131","57.5":"$57.5","106.5":"$106.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104.6111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$104.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,57.5,82,106.5,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.38,79.58153846153846,83.78307692307692,87.98461538461538,92.18615384615384,96.3876923076923,100.58923076923077,104.79076923076923,108.99230769230769,113.19384615384615,117.39538461538461,121.59692307692308,125.79846153846154,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.38,77.628547008547,79.87709401709401,82.12564102564102,84.37418803418802,86.62273504273503,88.87128205128204,91.11982905982904,93.36837606837605,95.61692307692306,97.86547008547006,100.11401709401709,102.3625641025641,{"y":104.6111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.38,75.35076923076923,75.32153846153845,75.29230769230769,75.26307692307692,75.23384615384614,75.20461538461538,75.17538461538462,75.14615384615385,75.11692307692307,75.08769230769231,75.05846153846154,75.02923076923076,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.38,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$130.00Average Price Target$104.61Lowest Price Target$75.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on IONS
Eliana Merle
Barclays
Barclays
$115
Buy
51.90%
Upside
Reiterated
06/26/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Ionis Pharmaceuticals (NASDAQ: IONS)
Wells Fargo Analyst forecast on IONS
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$100
Buy
32.08%
Upside
Reiterated
06/25/26
Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Needham Analyst forecast on IONS
Joseph Stringer
Needham
Needham
$105
Buy
38.69%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), Climb Bio (NASDAQ: CLYM) and Ionis Pharmaceuticals (NASDAQ: IONS)
H.C. Wainwright Analyst forecast on IONS
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$125→$130
Buy
71.71%
Upside
Reiterated
06/25/26
Ionis Pharmaceuticals price target raised to $130 from $125 at H.C. WainwrightIonis Pharmaceuticals price target raised to $130 from $125 at H.C. Wainwright
William Blair Analyst forecast on IONS
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)
TD Cowen Analyst forecast on IONS
Yaron Werber
TD Cowen
TD Cowen
$108
Buy
42.65%
Upside
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: Inmune Bio (INMB), AbSci (ABSI)
Bank of America Securities Analyst forecast on IONS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$111
Buy
46.61%
Upside
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Ionis Pharmaceuticals (IONS)
J.P. Morgan Analyst forecast on IONS
Jessica Fye
J.P. Morgan
J.P. Morgan
$80→$90
Buy
18.87%
Upside
Reiterated
06/24/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and InMode (NASDAQ: INMD)
Goldman Sachs Analyst forecast on IONS
Salveen Richter
Goldman Sachs
Goldman Sachs
$74→$75
Hold
-0.94%
Downside
Reiterated
06/24/26
Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman SachsIonis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs
Morgan Stanley Analyst forecast on IONS
Michael Ulz
Morgan Stanley
Morgan Stanley
$130
Buy
71.71%
Upside
Reiterated
06/24/26
Analyst Reiterates Buy on Tryngolza Launch Momentum; Maintains $130 Price Target
Canaccord Genuity Analyst forecast on IONS
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$110
Buy
45.29%
Upside
Reiterated
06/24/26
Ionis Buy Rating Reiterated as Tryngolza Launch Underpins Multibillion-Dollar Opportunity and Unchanged $110 Price Target
Jefferies Analyst forecast on IONS
Akash Tewari
Jefferies
Jefferies
$113
Buy
49.25%
Upside
Reiterated
06/15/26
Jefferies Remains a Buy on Ionis Pharmaceuticals (IONS)
Guggenheim Analyst forecast on IONS
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$106
Buy
40.01%
Upside
Reiterated
06/05/26
Ionis Pharmaceuticals (IONS) Receives a Buy from Guggenheim
Citi Analyst forecast on IONS
Eric Joseph
Citi
Citi
$90
Buy
18.87%
Upside
Initiated
05/20/26
J.P. Morgan Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Stifel Nicolaus Analyst forecast on IONS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$83→$86
Hold
13.59%
Upside
Reiterated
04/30/26
Stifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on IONS
Eliana Merle
Barclays
Barclays
$115
Buy
51.90%
Upside
Reiterated
06/26/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Ionis Pharmaceuticals (NASDAQ: IONS)
Wells Fargo Analyst forecast on IONS
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$100
Buy
32.08%
Upside
Reiterated
06/25/26
Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Needham Analyst forecast on IONS
Joseph Stringer
Needham
Needham
$105
Buy
38.69%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), Climb Bio (NASDAQ: CLYM) and Ionis Pharmaceuticals (NASDAQ: IONS)
H.C. Wainwright Analyst forecast on IONS
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$125→$130
Buy
71.71%
Upside
Reiterated
06/25/26
Ionis Pharmaceuticals price target raised to $130 from $125 at H.C. WainwrightIonis Pharmaceuticals price target raised to $130 from $125 at H.C. Wainwright
William Blair Analyst forecast on IONS
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)
TD Cowen Analyst forecast on IONS
Yaron Werber
TD Cowen
TD Cowen
$108
Buy
42.65%
Upside
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: Inmune Bio (INMB), AbSci (ABSI)
Bank of America Securities Analyst forecast on IONS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$111
Buy
46.61%
Upside
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Ionis Pharmaceuticals (IONS)
J.P. Morgan Analyst forecast on IONS
Jessica Fye
J.P. Morgan
J.P. Morgan
$80→$90
Buy
18.87%
Upside
Reiterated
06/24/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and InMode (NASDAQ: INMD)
Goldman Sachs Analyst forecast on IONS
Salveen Richter
Goldman Sachs
Goldman Sachs
$74→$75
Hold
-0.94%
Downside
Reiterated
06/24/26
Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman SachsIonis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs
Morgan Stanley Analyst forecast on IONS
Michael Ulz
Morgan Stanley
Morgan Stanley
$130
Buy
71.71%
Upside
Reiterated
06/24/26
Analyst Reiterates Buy on Tryngolza Launch Momentum; Maintains $130 Price Target
Canaccord Genuity Analyst forecast on IONS
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$110
Buy
45.29%
Upside
Reiterated
06/24/26
Ionis Buy Rating Reiterated as Tryngolza Launch Underpins Multibillion-Dollar Opportunity and Unchanged $110 Price Target
Jefferies Analyst forecast on IONS
Akash Tewari
Jefferies
Jefferies
$113
Buy
49.25%
Upside
Reiterated
06/15/26
Jefferies Remains a Buy on Ionis Pharmaceuticals (IONS)
Guggenheim Analyst forecast on IONS
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$106
Buy
40.01%
Upside
Reiterated
06/05/26
Ionis Pharmaceuticals (IONS) Receives a Buy from Guggenheim
Citi Analyst forecast on IONS
Eric Joseph
Citi
Citi
$90
Buy
18.87%
Upside
Initiated
05/20/26
J.P. Morgan Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Stifel Nicolaus Analyst forecast on IONS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$83→$86
Hold
13.59%
Upside
Reiterated
04/30/26
Stifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

3 Months
Myles MinterWilliam Blair
Success Rate
13/19 ratings generated profit
68%
Average Return
+16.84%
Copying Myles Minter's trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +16.84% per trade.
1 Year
Gary NachmanCanaccord Genuity
Success Rate
20/24 ratings generated profit
83%
Average Return
+34.60%
Copying Gary Nachman's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +34.60% per trade.
2 Years
Yanan ZhuWells Fargo
Success Rate
23/26 ratings generated profit
88%
Average Return
+59.86%
Copying Yanan Zhu's trades and holding each position for 2 Years would result in 88.46% of your transactions generating a profit, with an average return of +59.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
5
10
14
15
Buy
27
26
32
30
35
Hold
4
5
5
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
36
47
46
52
In the current month, IONS has received 50 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IONS average Analyst price target in the past 3 months is 104.61.
Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$1.06 with a range of -$1.26 to -$0.82. The previous quarter’s EPS was -$0.56. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.
Next quarter’s earnings estimate for IONS is -$1.06 with a range of -$1.26 to -$0.82. The previous quarter’s EPS was -$0.56. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $190.51M with a range of $162.90M to $211.00M. The previous quarter’s sales results were $246.09M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.
Next quarter’s sales forecast for IONS is $190.51M with a range of $162.90M to $211.00M. The previous quarter’s sales results were $246.09M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?
Based on analyst ratings, Ionis Pharmaceuticals Inc.’s 12-month average price target is 104.61.
    What is IONS’s upside potential, based on the analysts’ average price target?
    Ionis Pharmaceuticals Inc. has 38.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IONS a Buy, Sell or Hold?
          Ionis Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Ionis Pharmaceuticals Inc.’s price target?
            The average price target for Ionis Pharmaceuticals Inc. is 104.61. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $130.00 ,the lowest forecast is $75.00. The average price target represents 38.17% Increase from the current price of $75.71.
              What do analysts say about Ionis Pharmaceuticals Inc.?
              Ionis Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of IONS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.